William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 10,699 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $158.93, for a total value of $1,700,392.07. Following the completion of the transaction, the chief executive officer directly owned 306,891 shares in the company, valued at $48,774,186.63. This trade represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

William Lewis also recently made the following trade(s):

• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total transaction of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $166.97, for a total transaction of $1,786,412.03.

Insmed Price Performance

Insmed stock opened at $156.21 on Friday. The firm has a fifty day moving average of $184.40 and a 200-day moving average of $156.10. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $33.31 billion, a P/E ratio of -25.24 and a beta of 1.08.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The business had revenue of $142.34 million for the quarter, compared to analysts’ expectations of $114.33 million. During the same period last year, the company posted ($1.27) earnings per share. The firm’s revenue for the quarter was up 52.4% on a year-over-year basis. As a group, analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Institutional Trading of Insmed

Institutional investors have recently added to or reduced their stakes in the stock. CIBC Private Wealth Group LLC grew its holdings in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares in the last quarter. CoreCap Advisors LLC acquired a new position in Insmed in the fourth quarter worth about $27,000. ORG Partners LLC increased its holdings in Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 196 shares during the last quarter. Hilltop National Bank acquired a new stake in Insmed during the second quarter valued at approximately $28,000. Finally, Stone House Investment Management LLC bought a new position in Insmed during the 3rd quarter worth approximately $29,000.

Wall Street Analyst Weigh In

INSM has been the topic of several recent research reports. Morgan Stanley set a $157.00 price target on Insmed in a research report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research note on Wednesday, October 8th. TD Cowen set a $241.00 target price on shares of Insmed in a research note on Thursday, December 18th. Wedbush set a $203.00 price target on shares of Insmed in a report on Thursday, December 18th. Finally, Mizuho set a $212.00 price target on shares of Insmed in a research note on Thursday, December 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $204.68.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.